NCT00403494 - A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease | Biotech Hunter

Enrollment

190

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

January 31, 2009

Conditions

Intermittent Claudication

Interventions

OTHER

Placebo

Subjects receive matching oral Placebo twice daily for 24 weeks.

DRUG

Sapropterin Dihydrochloride

Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.

Trial Locations (20)

Scottsdale

Sacramento

San Diego

Santa Ana

Santa Rosa

Clearwater

Jacksonville

Conyers

Indianapolis

Auburn

Charlotte

Portland

Knoxville

Dallas

San Antonio

Norfolk

Richmond

Buenos Aires

Corrientes

Santa Fe